Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Anjum Owaisi"'
Autor:
Russell M. Petrak, Nathan C. Skorodin, Nicholas W. Van Hise, Robert M. Fliegelman, Jonathan Pinsky, Vishal Didwania, Michael Anderson, Melina Diaz, Kairav Shah, Vishnu V. Chundi, David W. Hines, Brian P. Harting, Kamo Sidwha, Brian Yu, Paul Brune, Anjum Owaisi, David Beezhold, Joseph Kent, Dana Vais, Alice Han, Neethi Gowda, Nishi Sahgal, Jan Silverman, Jonathan Stake, Jenie Nepomuceno, Renuka Heddurshetti
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2146-2151 (2021)
Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We evaluated patients treated with tocilizumab f
Externí odkaz:
https://doaj.org/article/8f2e979c953546579043c6871302879b
Autor:
Nicholas W. Van Hise, Vishnu Chundi, Neethi Gowda, Vishal Didwania, Jonathan Stake, Brian Yu, Kamo Sidwha, Nishi Sahgal, Michael Anderson, Paul Brune, Joseph Kent, Dana Vais, Jenie Nepomuceno, David W. Hines, Alice Han, Renuka Heddurshetti, Jan Silverman, Melina Diaz, Brian P. Harting, Russell M. Petrak, Kairav Shah, Anjum Owaisi, Jonathan Pinsky, Nathan C. Skorodin, Robert M. Fliegelman, David Beezhold
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 6, Pp 2146-2151 (2021)
Clinical and Translational Science, Vol 14, Iss 6, Pp 2146-2151 (2021)
BackgroundTocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with SARS-CoV-2.MethodsWe evaluated patients treated with tocilizumab for a SARS-CoV-2 infection who were admitte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8f0b99ab355743cbcb5ee6df91a382
https://doi.org/10.1101/2020.06.05.20122622
https://doi.org/10.1101/2020.06.05.20122622
